STOCK TITAN

Atea Pharmaceuticals (AVIR) SEC Filings

AVIR NASDAQ

Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.

Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.

Rhea-AI Summary

Atea Pharmaceuticals, Inc. director Bruno Lucidi exercised options to acquire 21,628 shares on November 17, 2026 at an exercise price of $1.24 per share, then sold 6,741 shares at a weighted-average price of $4.0335. On November 19, 2026, he exercised options to acquire 53,372 shares at $1.24 per share and sold 22,619 shares at a weighted-average $3.9445. The sales were reported as paying option exercise costs and serving tax-planning purposes; no Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Atea Pharmaceuticals director Bruce Polsky sold 8,750 shares of common stock on November 19, 2026, at a weighted-average price of $4.0341 per share. The sales occurred in multiple transactions priced from $4.00 to $4.04. He directly held 149,830 shares after the sale. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. director Bruno Lucidi reported a proposed sale of 22,619 common shares, with an aggregate market value of $89,219.37 and an approximate sale date of November 19, 2026. The notice names Morgan Stanley Smith Barney LLC as broker. Lucidi acquired the shares on November 19, 2026, through a stock option exercise from the issuer, with cash payment. It also reports a sale of 6,741 common shares on November 17, 2026, for gross proceeds of $27,189.82.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (AVIR) director Bruce Polsky reported a proposed sale of 8,750 common shares, with an aggregate market value of $35,299.25 and an approximate sale date of November 19, 2026. The shares were acquired from the issuer on November 16, 2026, in an exercised-shares transaction paid for in cash. The notice also lists three sales during the past three months: 14,254 shares for gross proceeds of $60,840.35 on November 16; 8,720 shares for $35,155.55 on November 17; and 18,252 shares for $72,099.05 on November 18, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (AVIR) director Bruce Polsky exercised 75,000 stock options at $1.24 per share from November 16 through November 18, 2026, receiving common shares. He sold 41,226 shares across those dates: 14,254 at a weighted average $4.2683 on November 16, 8,720 at $4.0316 on November 17, and 18,252 at $3.9502 on November 18. The sales were reported as executed to pay the options’ exercise price and for tax-planning purposes. The options were fully vested and exercisable, and no Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Atea Pharmaceuticals (AVIR) director Bruce Polsky gave notice of a proposed sale of 18,252 common shares, with an aggregate market value of $72,099.05 and an approximate sale date of November 18, 2026. The notice lists those shares as acquired from the issuer through a stock option exercise paid in cash on November 18, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (AVIR) lists a Form 144 notice for director Bruce Polsky to sell 8,720 common shares, with an aggregate market value of $35,155.55 and an approximate sale date of November 17, 2026. The notice also reports that he sold 14,254 common shares on November 16, 2026, for gross proceeds of $60,840.35 during the preceding three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
other
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (AVIR) director Bruno Lucidi gave notice of a proposed sale of 6,741 common shares, with an aggregate market value of $27,189.82 and an approximate sale date of November 17, 2026. The shares were acquired from the issuer through a stock option exercise on November 17, 2026, with cash listed as the nature of payment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
other
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (AVIR) director Bruce Polsky reported a proposed sale of 14,254 common shares, with an aggregate market value of $60,840.35 and an approximate sale date of November 16, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
other
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (AVIR) ownership amendment reports that JPM Partners LLC beneficially owned 5,116,025 shares, or 6.4% of the class, with shared voting and dispositive power. Jean-Pierre Sommadossi reported beneficial ownership of 9,080,450 shares, or 11.0%, including the shares held by JPM Partners LLC and an additional 3,964,425 shares.

Of Sommadossi’s additional shares, 2,446,595 were subject to stock options that were exercisable or would become exercisable within 60 days of September 30, 2026. The ownership figures are as of September 30, 2026, based on 80,304,145 shares outstanding as of November 6, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
ownership

FAQ

How many Atea Pharmaceuticals (AVIR) SEC filings are available on StockTitan?

StockTitan tracks 58 SEC filings for Atea Pharmaceuticals (AVIR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Atea Pharmaceuticals (AVIR)?

The most recent SEC filing for Atea Pharmaceuticals (AVIR) was filed on November 19, 2026.